Key Takeaways
Trulieve Cannabis Corp. (OTCQX: TCNNF) reported a profitable first quarter with net income of $2 million and $287 million in revenue, positioning the company to capitalize on the recent rescheduling of medical marijuana.
"With 206 dispensaries and over 3.5 million square feet of production serving medical patients, Trulieve is well positioned to explore new opportunities enabled by rescheduling," said Kim Rivers, Trulieve CEO.
The profitable quarter and positive cash flow provide a solid foundation as Trulieve seeks to expand its operations under the new federal guidelines for medical cannabis. The company's applications for DEA registration represent a key step in this process.
The Florida-based cannabis company announced first-quarter revenue of $287 million, a four percent decrease from the same period last year. However, the company swung to a net income of $2 million, compared to a net loss of $33 million in the first quarter of 2025. Adjusted EBITDA was $100 million, or 35 percent of revenue.
Trulieve generated $56 million in cash flow from operations and $42 million in free cash flow during the quarter. The company's cash position stood at $353 million at the end of March.
The recent decision by the Trump Administration to reclassify medical marijuana to Schedule III under the Controlled Substances Act has enabled Trulieve to file applications with the Drug Enforcement Agency (DEA) to register its 206 retail locations. The company has also been expanding its retail footprint, opening seven new dispensaries in Florida since the beginning of the year.
The return to profitability and strong cash generation demonstrate a solid operational footing for Trulieve. Investors will be watching for updates on the company's DEA registration applications and how the rescheduling of cannabis impacts the company's growth and profitability in the coming quarters.
This article is for informational purposes only and does not constitute investment advice.
